Indoleamine 2，3-dioxygenase 1 inhibitor for the treatment of bladder cancer—Linrodostat

doi:10.3969/j.issn.1672-3384.2022.03.006

PDF(382 KB)

Clinical Medication Journal ›› 2022, Vol. 20 ›› Issue (3) : 27-30. DOI: 10.3969/j.issn.1672-3384.2022.03.006

Comment of new drugs

Indoleamine 2，3-dioxygenase 1 inhibitor for the treatment of bladder cancer—Linrodostat

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2022, 20(3): 27-30 https://doi.org/10.3969/j.issn.1672-3384.2022.03.006

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(382 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2021-07-31	2022-03-30
Issue Date
2022-03-30

Please choose a citation manager

Content to export